Cytek Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cytek Biosciences (CTKB).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

3Buy

1Sell

Consensus RatingOverweight# Analysts4Avg. Consensus PT$5Upside to Avg. PT+10.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 13, 2026	Stephens & Co.	Mason Carrico	PT Cut	Overweight	$6→$5
May 12, 2026	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$6→$6
Jan 8, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$4→$5
Nov 11, 2025	Piper Sandler	David Westenberg	PT Cut	Overweight	$8→$8
May 28, 2025	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$9→$7
May 12, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Sell	$4→$3
Mar 19, 2025	Stephens & Co.	Mason Carrico	Maintained	Overweight	$6
Mar 4, 2025	Piper Sandler	David Westenberg	PT Cut	Overweight	$9→$8
Mar 3, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Sell	$5→$5
Feb 3, 2025	Goldman Sachs	Matthew Sykes	PT Raise	Sell	$5→$5
Jan 31, 2025	Goldman Sachs	Matthew Sykes	Downgrade	Buy→Sell	$7→$5
Nov 11, 2024	Piper Sandler	David Westenberg	PT Raise	Overweight	$8→$9
Aug 13, 2024	Piper Sandler	David Westenberg	PT Cut	Overweight	$9→$8
Aug 7, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$8→$7
May 13, 2024	Piper Sandler	David Westenberg	PT Cut	Overweight	$10→$9
May 10, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$9→$8
Mar 6, 2024	Piper Sandler	David Westenberg	PT Cut	Overweight	$11→$10
Feb 29, 2024	Goldman Sachs	Matthew Sykes	PT Raise	Buy	$9→$10
Dec 14, 2023	Stephens & Co.	Mason Carrico	Initiate	Overweight	$9
Nov 9, 2023	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$8→$7

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

Stephens & Co. analyst Mason Carrico maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $5.5 to $4.75.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $6 to $5.5.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5

TD Cowen analyst Brendan Smith maintains Cytek Biosciences (NASDAQ:CTKB) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5

Piper Sandler analyst David Westenberg maintains Cytek Biosciences (NASDAQ:CTKB) with a Overweight and lowers the price target from $8 to $7.5.

Benzinga Newsdesk

Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock

Benzinga Insights

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $9 to $7.

Benzinga Newsdesk

Cytek Biosciences Inc

Cytek Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

PRO
TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5

PRO
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5

Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

People Also Watch

People Also Watch

Benzinga

Benzinga

Cytek Biosciences Inc

Cytek Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROStephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

PROMorgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

PROTD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5

PROPiper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5

Beyond The Numbers: 4 Analysts Discuss Cytek Biosciences Stock

PROMorgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

People Also Watch

People Also Watch

PRO
Stephens & Co. Maintains Overweight on Cytek Biosciences, Lowers Price Target to $4.75

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $5.5

PRO
TD Cowen Maintains Buy on Cytek Biosciences, Raises Price Target to $5

PRO
Piper Sandler Maintains Overweight on Cytek Biosciences, Lowers Price Target to $7.5

PRO
Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7